New legislation will make it easier for startups to raise capital, but looser regulations on disclosure and research will make the IPO market less attractive for investors, says Morningstar's Heather Brilliant.
Health-care analyst Brian Laegeler likes the fact that specialty pharma IPO Cumberland is already profitable, but a weak pipeline and a pricey offer price are concerns.
IPO volume reached $43 billion in 2012, the highest amount since $49 billion in 2007, reports Renaissance Capital, which tracks IPOs. What can advisors expect for 2013?